Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024 Mar 21, 2024
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections Jan 30, 2024
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023 Nov 7, 2023
Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections Oct 24, 2023
